Endoscopy in clinics of inflammatory bowel disease

Gastroenterological Endoscopy

Volumn 48, Issue 3, 2006, Pages 291-302

  Matsui, Toshiyuki ^a   Wada, Yoko ^a   Hirai, Fumihito ^a   Sou, Suketo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; GLUCOCORTICOID; INFLIXIMAB; MESALAZINE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; TSUKUBAENOLIDE; TUMOR NECROSIS FACTOR ALPHA;

CAPSULE ENDOSCOPY; CROHN DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DOUBLE BALLOON ENDOSCOPY; ENTERITIS; GASTROINTESTINAL ENDOSCOPY; HUMAN; PATHOPHYSIOLOGY; REVIEW; ULCERATIVE COLITIS;

EID: 33645716205     PISSN: 03871207     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Matts SGF. The value of rectal biopsy in the diagnosis of ulcerative colitis. Quart J Med 1961; 30: 393-407.
2. Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964; 298: 89-92.
3. Rachmilewitz D. Coated mesalamine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. Br Med J. 1989; 273: 82-6.
4. Blackstone MO. Differentiation of ulcerative colitis from Crohn's colitis. In Blackstone MO, ed. Endoscopic interpretation: normal and pathologic appearance of the gastrointestinal tract. New York, Raven 1984; 464-96.
5. Wada Y, Matsui T, Matake H, et al. Intractable ulcerative colitis caused by cytomegalovirus infection: A prospective study on prevalence, diagnosis and treatment. Dis Colon Rectum 2003; 46 (suppl)): S59-S65.
6. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987; 92: 1894-8.
7. Seo M, Okada M, Yao T, et al. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992; 87: 971-6.
8. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut 1998; 43: 29-32.
9. Sutherland LR, Xiao LF. Clinical trial design with an emphasis on indices to measure disease activity. In Kirsner's Inflammatory Bowel Disease, sixth ed, Sartor RB, Sandborn WL ed. Saunders, London, 2004 pp 453-pp 468.
10. Sands BE, Abreu MT, Ferry GD, et al. Design issues and outcomes in IBD clinical trials. Inflamm Bowel Dis 2005; 11: S22-S8.
11. Fera A, Bellando P, Caldera D, et al. Colonoscopy in IBD: diagnostic accuracy and proposal of an endoscopic score. Gastroenterology 1987; 92: 181-5.
12. Vermeire S, Peeters M, Rutgeerts P. Diagnostic approach to IBD. Hepatogastroenterology 2000; 47: 44-8.
13. Matsui T, Yao T, Sakurai T, et al. Clinical features and pattern of indeterminate colitis: Crohn's disease with ulcerative colitis-like presentation. J Gastroenterol 2003; 38: 647-55.
14. Modigliani R, Mary JY, Simon JF, et al. Clinical biological and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Grouge d'Etude Therapeutique des Affection s Inflammatoires Digestives. Gastroenterology 1997; 98: 811-8.
15. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004; 60: 505-12.
16. Yao T, Okada M, Fuchigami T, et al. The relationship between the radiological and clinical features in patients with Crohn's disease. Clin Radiol. 1989; 40: 389-92.
17. th UEGW, 1995.
18. Sou S, Matsui T, Yao T, et al. Clinical and endoscopic healing after infliximab treatment in patients with Crohn's disease. Digest Endosc 2006; 18: 29-33.
19. Hommes D, Baert F, Van Assche G, et al. Management of recent onset Crohn's disease: A controlled, randomized trial comparing step-up and top-down therapy. Gastroenterology 2005; 129: 371.
20. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2000, 359; 1541-9.
21. D'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 1999; 116: 1029-34.
22. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999; 117: 761-9.
23. Rutgeerts P, Van Assche G, Van Deventer S, et al. Infliximab maintenance strategy results in mucosal healing in patients with Crohn's disease [abstract]. Gastroenterology 2002; 122: A 619.
24. D'Haens G, Noman M, Baert F, et al. Endoscopic healing after infliximab treatment for Crohn's disease provides a longer time to relapse [abstract]. Gastroenterology 2002; 122: A 100.
25. D'Haens G. Mucosal healing in pediatric Crohn's disease: the goal of medical treatment. Inflamm Bowel Dis. 2004; 10: 479-80.
26. Rutgeerts P. Does mucosal healing make a difference in Crohn's disease. 2005 DDW Abstract pp 190-3.
27. D'Haens G, Geboes K, Ponette E, et al. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 1997; 112: 1475-81.
28. D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc 1999; 50: 667-71.
29. Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004; 127: 723-9.
30. D'Haens G. Infliximab as disease-modifying therapy. Eur J Gastroenterol Hepatol. 2003; 15: 233-7.
31. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of Certolizumab Pegol (CDP 870) for treatment of Crohn's disease. Gastroenterology 2005; 129: 807-18.
32. Yamamoto H, Kita H. Enteroscopy. J Gastroenterol 2005; 40: 555-62.
33. Yamamoto H, Seike Y, Sato Y, et al. Total enteroscopy with a nonsurgical steerable double-balloon method. Gastrointestinal Endosc 2001; 53: 216-20.
34. Matsui T, Ikeda K, Tsuda S, et al. Long-term outcome of endoscopic balloon dilation in obstructive gastrointestinal Crohn's disease: A prospective long-term study. Diag Ther Endosc 2000; 6: 67-75.
35. Matsui T, Tsuda S, Matake H, et al. Long-term outcome of endoscopic balloon dilation in obstructive gastrointestinal Crohn's disease. Digest Endosc 2004; 16 (Suppl): S27-S30.
36. Yamamoto H, Kita H, Sunada T, et al. Clinical outcome of double balloon endoscopy for the diagnosis and treatment of small intestinal-diseases. Clin Gastroenterol Hepatol 2004; 2: 1010-6.